Proteome Sciences is pleased to announce the completion of installation and setup of equipment in its new US laboratory in San Diego, California. and is therefore now fully operational.
The Company announces a trading update to its shareholders.
Proteome Sciences plc is pleased to announce the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents.
Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Half Year Results via the Investor Meet Company platform on 19th September 2023 at 10:00am BST.
Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2023.
The Directors of Proteome are pleased to announce that the Company has today repaid in full the outstanding loan and associated interest (together totalling £824,424) to Vulpes Investment Management Private Limited originally announced on 2 July 2018 and amended on 30 March 2022.
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 p.m. today, all resolutions were duly passed.
Annual General Meeting (AGM) Statement
Proteome Sciences plc is pleased to announce the expansion of its proteomics services into the United States of America (“US”).